Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status

Thrombosis Research

Volumn 126, Issue 6, 2010, Pages

  O'Sullivan, Eoin P ^a,b   Ashley, David T ^a,b   Davenport, Colin ^a,b   Kelly, James ^a,b   Devlin, Niamh ^a,b   Crowley, Rachel ^a,b   Leahy, Austin L ^a,b   Kelly, Cathal J ^a,b   Agha, Amar ^a,b   Thompson, Christopher J ^a,b   O'Gorman, Donal J ^a,b   Fitzgerald, Patricia ^a,b   Smith, Diarmuid ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Diabetes; Osteoprotegerin; Peripheral arterial disease; Vascular calcification

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGE DISTRIBUTION; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC FOOT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT AMPUTATION; FOOT ULCER; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE;

EID: 78649737502     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.09.003     Document Type: Article

References (36)

1. A.T. Hirsch, M.H. Criqui, D. Treat-Jacobson, J.G. Regensteiner, M.A. Creager, and J.W. Olin Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 11 Sep 19 2001 1317 1324
2. R.J. Rennenberg, A.G. Kessels, L.J. Schurgers, J.M. van Engelshoven, P.W. de Leeuw, and A.A. Kroon Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis Vasc Health Risk Manag 5 1 2009 185 197
3. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, and C. Silverman Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 23 Jun 5 1998 14363 14367
4. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, and C. Capparelli Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 9 May 1 1998 1260 1268
5. H. Min, S. Morony, I. Sarosi, C.R. Dunstan, C. Capparelli, and S. Scully Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis J Exp Med 192 4 Aug 21 2000 463 474
6. P.A. Price, H.H. June, J.R. Buckley, and M.K. Williamson Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D Arterioscler Thromb Vasc Biol 21 10 Oct 2001 1610 1616
7. D.V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects J Am Coll Cardiol 47 9 May 2 2006 1850 1857
8. S. Jono, Y. Ikari, A. Shioi, K. Mori, T. Miki, and K. Hara Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation 106 10 Sep 3 2002 1192 1194
9. M. Schoppet, A.M. Sattler, J.R. Schaefer, M. Herzum, B. Maisch, and L.C. Hofbauer Increased osteoprotegerin serum levels in men with coronary artery disease J Clin Endocrinol Metab 88 3 Mar 2003 1024 1028
10. E.J. Rhee, W.Y. Lee, S.Y. Kim, B.J. Kim, K.C. Sung, and B.S. Kim Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein Clin Sci (Lond) 108 3 Mar 2005 237 243
11. W.S. Browner, L.Y. Lui, and S.R. Cummings Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women J Clin Endocrinol Metab 86 2 Feb 2001 631 637
12. S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, and A. Mayr Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease Circulation 109 18 May 11 2004 2175 2180
13. T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, and T. Omland Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction J Am Coll Cardiol 44 10 Nov 16 2004 1970 1976
14. T. Omland, T. Ueland, A.M. Jansson, A. Persson, T. Karlsson, and C. Smith Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes J Am Coll Cardiol 51 6 Feb 12 2008 627 633
15. P. Pennisi, S.S. Signorelli, S. Riccobene, G. Celotta, L. Di Pino, and T. La Malfa Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels Osteoporos Int 15 5 May 2004 389 395
16. S. Ziegler, S. Kudlacek, A. Luger, and E. Minar Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease Atherosclerosis 182 1 Sep 2005 175 180
17. A. Avignon, A. Sultan, C. Piot, D. Mariano-Goulart, J.F. Thuan Dit Dieudonne, and J.P. Cristol Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients Diabetes Care 30 11 Nov 2007 2934 2939
18. M. Koshikawa, K. Aizawa, H. Kasai, A. Izawa, T. Tomita, and S. Kumazaki Elevated osteopontin levels in patients with peripheral arterial disease Angiology 60 1 Feb-Mar 2009 42 45
19. S.T. Knudsen, C.H. Foss, P.L. Poulsen, N.H. Andersen, C.E. Mogensen, and L.M. Rasmussen Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications Eur J Endocrinol 149 1 Jul 2003 39 42
20. S.M. Kim, J. Lee, O.H. Ryu, K.W. Lee, H.Y. Kim, and J.A. Seo Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity Clin Endocrinol (Oxf) 63 5 Nov 2005 594 598
21. G.D. Xiang, L. Xu, L.S. Zhao, L. Yue, and J. Hou The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes Diabetes 55 7 Jul 2006 2126 2131
22. P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, and B. Fabris An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction Am J Pathol 169 6 Dec 2006 2236 2244
23. S. Yaturu, J. Rains, and S.K. Jain Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes Cytokine 44 1 Oct 2008 168 171
24. H.M. Terekeci, M.G. Senol, C. Top, B. Sahan, S. Celik, and O. Sayan Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy Exp Clin Endocrinol Diabetes 117 3 Mar 2009 119 123
25. Z. Ali, A.A. Ellington, T.H. Mosley Jr., and I.J. Kullo Association of serum osteoprotegerin with ankle-brachial index and urine albumin: Creatinine ratio in African-Americans and non-Hispanic whites Atherosclerosis 206 2 Oct 2009 570 580
26. L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, and F.G. Fowkes Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 45 Suppl S Jan 2007 S5 S67
27. J.A. Kanis Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4 6 Nov 1994 368 381
28. N.X. Chen, and S.M. Moe Arterial calcification in diabetes Curr Diab Rep 3 1 Feb 2003 28 32
29. J.K. Jensen, T. Ueland, D. Atar, L. Gullestad, H. Mickley, and P. Aukrust Osteoprotegerin concentrations and prognosis in acute ischaemic stroke J Intern Med 267 4 Apr 2010 410 417
30. M.M. McDermott, and D.M. Lloyd-Jones The role of biomarkers and genetics in peripheral arterial disease J Am Coll Cardiol 54 14 Sep 29 2009 1228 1237
31. I.M. Van Der Meer, M.P. De Maat, A.E. Hak, A.J. Kiliaan, A.I. Del Sol, and D.A. Van Der Kuip C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study Stroke 33 12 Dec 2002 2750 2755
32. I. Tzoulaki, G.D. Murray, A.J. Lee, A. Rumley, G.D. Lowe, and F.G. Fowkes C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study Circulation 112 7 Aug 16 2005 976 983
33. K. Sato, A. Niessner, S.L. Kopecky, R.L. Frye, J.J. Goronzy, and C.M. Weyand TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque J Exp Med 203 1 Jan 23 2006 239 250
34. P. Secchiero, R. Candido, F. Corallini, S. Zacchigna, B. Toffoli, and E. Rimondi Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice Circulation 114 14 Oct 3 2006 1522 1530
35. F. Corallini, C. Celeghini, C. Rizzardi, A. Pandolfi, S. Di Silvestre, and M. Vaccarezza Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro J Cell Physiol 212 1 Jul 2007 89 95
36. P. Mezquita-Raya, M. de la Higuera, D.F. Garcia, G. Alonso, M.E. Ruiz-Requena, and J. de Dios Luna The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women Osteoporos Int 16 11 Nov 2005 1368 1374